Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") is pleased to announce the launch of the first of what is expected to be a range of products, in partnership with Geocann, which will utilize the advanced VESIsorb ® delivery system. This technology provides better bioavailability and faster absorption. VESIsorb ® formulations have set the industry benchmark in peer-reviewed published studies, delivering superior pharmacokinetic performance, including fast absorption, higher plasma concentration, and greater area under the curve.
"We are committed to bringing breakthrough innovations to the market, providing consumers with differentiated and high-quality products," said Mike Gorenstein, Chairman, President and Chief Executive Officer, Cronos. "Working with Geocann's technology enables us to expand our product offering to bring consumers a fast-acting cannabinoid product with a quicker onset than previously available, along with improved efficacy, helping enhance and differentiate effect and experience."
VESIsorb ® is the leading delivery system innovation for dramatically improving the bioavailability of difficult-to-absorb ingredients, like cannabinoids and terpenes. This patented technology has been shown to have faster absorption in both well-designed pilot and peer-reviewed published studies. Geocann is the exclusive supplier of the VESIsorb ® delivery system for cannabinoids, terpenes, and flavonoid formulations, and is well-recognized for its substantial investments in research and product development in order to meet the needs of the marketplace.
"As leading companies in our respective sectors, Geocann and Cronos are uniquely positioned to set new industry benchmarks for the performance of cannabinoid products," Jesse Lopez, Chief Executive Officer and founder of Geocann, said. "Most importantly, Geocann is proud to support the innovative brands under the Cronos umbrella."
The first VESIsorb ® formulated product the companies have launched together are the CBD Gel Capsules by Lord Jones ® . The companies look forward to collaborating in the future on innovative products and formulations.
About Cronos Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach ® , PEACE NATURALS ® , Lord Jones ® , Happy Dance ® and PEACE+™. For more information about Cronos and its brands, please visit: thecronosgroup.com.
Cronos Group Contact Shayne Laidlaw Investor Relations Tel: (416) 504-0004 investor.relations@thecronosgroup.com
About Geocann Geocann is a global cannabis organization that combines clinically-researched cannabinoids and terpenes with technologically-advanced drug delivery system technologies that increase absorption and bioavailability for maximum health benefits. These product formulations offer novel solutions that address unmet marketplace needs and provide unmatched competitive advantages that are backed by a robust body of clinical studies and proprietary scientific evidence. Geocann owns a robust intellectual property portfolio, including the worldwide exclusivity for cannabinoids, terpenes, and flavonoids formulated with the VESIsorb ® drug delivery system technology platform. For more information, please visit www.geocann.com .
For more information and interview requests, please contact Sam Davidson at + 1 970-657-2479 or sam@geocann.com .
Forward-looking Statements of Cronos Group Inc. This press release may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include the companies' launch of a range of products and future collaboration on innovative products and formulations and Cronos' intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the period ended March 31, 2022, both have which been filed on SEDAR and EDGAR and can be accessed at www.sedar.com and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos Group disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.
News Provided by GlobeNewswire via QuoteMedia
An article curated by Bazinga highlighted the cannabis market trends from last week. Even though last week was short, the cannabis sector was a busy. The article went on to highlight a number of the cannabis companies looking preparing for their IPOs, among other cannabis related news.
The article went on to highlight the Flowr Corporation as one of numerous companies looking to go public by the end of the year. Flowr’s management team is responsible for the creation and success of MedReleaf, an R&D focused company in the medical cannabis space. In preparation for its RTO in Canada, the company has raised $36 million in financing.
The article went on to talk about other deals that were announced over the past week, including deals between Indiva Ltd. (TSXV: NDVA ) and MediPharm Labs and Cronos Group (TSX: CRON ) and Ginkgo Bioworks.
To read the full article, click here .
Click here to connect with The Flowr Corporation for an Investor Presentation.
Subsequent to this press release, The Flowr Corporation went public on September 26, 2018 under the ticker symbol TSXV:FLWR.
Overwhelming Columbia Care shareholder support with 98.5% of votes cast in favor of the business combination
Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) ("Columbia Care" or the "Company"), one of the largest and most experienced cultivators, manufacturers and providers of cannabis products in the U.S., announced that at the special meeting (the "Meeting") of shareholders of the Company ("Shareholders") held today, July 8, 2022, the proposed business combination with Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) ("Cresco Labs") was approved.
The Shareholders voted in favor of a special resolution to approve the previously announced plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia) whereby, among other things, Cresco Labs will acquire all of the issued and outstanding shares of the Company, all as more particularly described in detail in the Company's definitive proxy statement and information circular dated June 6, 2022 (the "Circular") filed on SEDAR and with the United States Securities and Exchange Commission.
Voting results are as follows:
Percentage of shares (1) that were voted
(1) Assuming conversion of all proportionate voting shares into common shares.
At the Meeting, a total of 169,938,646 Columbia Care Shares were represented in person or by proxy, representing 42.6% of the Columbia Care Shares issued and outstanding as of the close of business on May 10, 2022 (the "Record Date") and entitled to vote at the Meeting as of the Record Date.
"We are grateful for the overwhelming support of our shareholders as we move forward with the combination with Cresco Labs that will reshape the industry and redefine leadership in cannabis," said Nicholas Vita, Co-Founder, CEO of Columbia Care. "As we celebrate this milestone, we remain steadfast in executing our strategic objectives through the close of the transaction, which we anticipate will be near the end of this year."
Full details are contained in the Report of Voting Results for the Meeting, which has been filed on SEDAR at www.sedar.com .
Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 18 U.S. jurisdictions and the EU. Columbia Care operates 131 facilities including 99 dispensaries and 32 cultivation and manufacturing facilities, including those under development. Columbia Care is one of the original multi-state providers of medical cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the company launched Cannabist, its new retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, gLeaf, Classix, Press, Amber and Platinum Label CBD. For more information on Columbia Care, please visit https://columbia.care .
Caution Concerning Forward Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements or information, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. These risks, uncertainties and other factors include, among others, favorable operating and economic conditions; the completion of the Arrangement; obtaining and maintaining all required licenses and permits; favorable production levels and sustainable costs from the Company's operations; and the level of demand for cannabis products, including the Company's products sold by third parties. In addition, securityholders should review the risk factors discussed under "Risk Factors" in the Circular and "Risk Factors" in Columbia Care's Form 10 dated May 9, 2022, filed with the applicable securities regulatory authorities and described from time to time in documents filed by the Company with Canadian and U.S. securities regulatory authorities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220708005479/en/
Investor Contact Lee Ann Evans SVP, Capital Markets ir@col-care.com Media Contact Lindsay Wilson VP, Communications +1.978.662.2038 media@col-care.com
News Provided by Business Wire via QuoteMedia
This press release corrects a prior version published on July 7, 2022 to update the timing for effectiveness of the registration statement. Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., announced that it filed a shelf registration statement on Form S-3 (the Registration Statement) with the United States Securities and Exchange Commission ("SEC") on July 7, 2022 to register a base shelf prospectus and to register for resale select subordinate voting shares of the Company. The Registration Statement is expected to become effective upon its acceptance by the SEC.
The Company became eligible to file the S-3 registration statement following one year of reporting under the previously filed registration statement and associated amendments on Form S-1. The S-3 filing provides a shelf registration which may provide the Company with additional flexibility in its future financing opportunities. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement. The resale prospectus covers the resale registration by Selling Shareholders of up to 72,288,199 subordinate voting shares. Selling Shareholders may offer, sell or distribute all or a portion of their Subordinate Voting Shares publicly or through private transactions at prevailing market prices or at negotiated prices. However, the registration of the securities covered by the Registration Statement does not necessarily indicate that the Company and/or Selling Shareholders will offer or sell any Subordinate Voting Shares in connection with such registration or within any specific timeframe.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.
The Company has filed a registration statement (including a prospectus) with the SEC for the registration of shares to which this communication relates. You should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and any applicable offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov . Alternatively, the Company and any participant in any applicable offering will arrange to send you the prospectus if you request it by calling toll-free 1-844-878-5438.
About Trulieve Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .
Facebook: @Trulieve Instagram: @Trulieve _ Twitter: @Trulieve
Investor Contact Christine Hersey , Executive Director of Investor Relations +1 (424) 202-0210 Christine.Hersey@Trulieve.com
Media Contact Rob Kremer , Executive Director of Corporate Communications +1 (404) 218-3077 Robert.Kremer@Trulieve.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/correction--trulieve-announces-registration-statement-filing-301582947.html
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2022/08/c7003.html
News Provided by Canada Newswire via QuoteMedia
Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it publicly filed an automatically effective registration statement on Form S-3 (the Registration Statement) with the United States Securities and Exchange Commission ("SEC") on July 7, 2022 to register a base shelf prospectus and to register for resale select Subordinate Voting Shares of the Company.
The Company became eligible to file the S-3 registration statement following one year of reporting under the previously filed registration statement and associated amendments on Form S-1. The S-3 filing provides a shelf registration which may provide the Company with additional flexibility in its future financing opportunities. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement. The resale prospectus covers the resale registration by Selling Shareholders of up to 72,288,199 subordinate voting shares. Selling Shareholders may offer, sell or distribute all or a portion of their Subordinate Voting Shares publicly or through private transactions at prevailing market prices or at negotiated prices. However, the registration of the securities covered by the Registration Statement does not necessarily indicate that the Company and/or Selling Shareholders will offer or sell any Subordinate Voting Shares in connection with such registration or within any specific timeframe.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.
About Trulieve Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .
Facebook: @Trulieve Instagram: @Trulieve_ Twitter: @Trulieve
Investor Contact Christine Hersey , Executive Director of Investor Relations +1 (424) 202-0210 Christine.Hersey@Trulieve.com
Media Contact Rob Kremer , Executive Director of Corporate Communications +1 (404) 218-3077 Robert.Kremer@Trulieve.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-registration-statement-filing-301582682.html
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2022/07/c7557.html
News Provided by Canada Newswire via QuoteMedia
The exclusive distribution agreement with Bio-Gate AG includes 5 SKUs from Pura H&W's evidence-based derma-cosmetics portfolio
Initial portfolio launch is planned for Germany, Austria, and Switzerland in Q3 2022
Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that the Company has completed its first commercial export of its evidence-based derma-cosmetic line Pura H&W (" Pura " or " Pura Health & Wellness" ) into the European Market as a part of its supply and distribution agreement with Bio-Gate AG (" Bio-Gate ").
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bab76054-b480-4a1c-9d7a-0b8d3813b05b
Avicanna's evidence-based derma-cosmetics portfolio has now been successfully imported into Germany where Bio-Gate prepare to launch this summer. The portfolio of products will initially be available online at http://www.purahw.com and then further expanded into other online, retail and pharmacy channels across Germany, Austria, and Switzerland during 2022.
"We are pleased to be entering the European market with our first line of branded products and to be doing so in collaboration with Bio-Gate. Both teams are excited about the launch of the skincare portfolio in the coming months and are happy to see the Pura Health and Wellness brand establish a new European foothold," commented Jens Kramer, VP of European Operations at Avicanna.
To its knowledge, Avicanna carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.
About Pura H&W
Pura Health & Wellness (Pura H&W) is Avicanna's derma-cosmetic line which utilizes a combination of purified CBD and other synergistic botanical ingredients designed to naturally regulate and nourish the skin. The Pura H&W product line was developed by Avicanna and specific products have undergone clinical trials. The products are now commercial under Pura H&W or Pura Earth in Canada, Colombia, Ecuador, the U.S.
The Pura H&W formulations have been developed and optimized to deliver purified, THC-free CBD in synergistic combinations with other natural ingredients known to provide specific functional benefits in skincare. CBD has been shown to promote skin health by inducing antioxidant, anti-inflammatory, and anti-apoptotic responses that could be beneficial for a variety of dermatological conditions such as eczema or atopic dermatitis. In addition, CBD can down-regulate the activity of cells that are critical in the production of skin oils and therefore may dampen the production in acne-prone skin.
Bio-Gate AG is a health technology company and a leading provider of innovative technologies and products for health, infection control and hygiene that can make living together safer and healthier, and improve the well-being of each individual. Bio-Gate specializes in providing materials and surfaces with antiviral, antimicrobial or biologically active properties. Bio-Gate AG enhances materials and products, particularly in the field of medical technology, for example in the coating of implants or wound dressings. In addition, Bio-Gate technologies are used in dermatological active cosmetics and wound care products, as well as consumer and industrial products.
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:
Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol ("CBD") and tetrahydrocannabinol ("THC"). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.
Pharmaceutical Pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna's first pharmaceutical preparation (Trunerox™) is in the drug registration stage in South America.
Click to watch Avicanna's Corporate Video 2022
For more information about Avicanna, visit www.Avicanna.com, contact Ivana Maric by email at info@Avicanna.com or follow us on social media on LinkedIn , Twitter , Facebook or Instagram .
The Company posts updates through videos from the official Company YouTube channel.
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified using words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated March 31, 2022 filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
News Provided by GlobeNewswire via QuoteMedia
Location opens on July 6 ; grand opening celebration scheduled for July 9
Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of its Trulieve medical dispensary in Hurricane, West Virginia . Located at 2 Putnam Village Dr. Suite 2-3 the new dispensary will open its doors at 10am on Wednesday, July 6, 2022 . This is the Company's sixth retail location in West Virginia and will be open seven days a week from 10am to 6pm .
Grand opening festivities will be held on Saturday, July 9 throughout the day to include partner giveaways, deals and specials, and all registered patients will receive a 25% discount. On-site medical care specialists will be available to assist with medical card registration and certification for West Virginia patients.
"We are excited to expand medical cannabis to Hurricane while creating jobs in the area," said Trulieve Chief Executive Officer Kim Rivers . "In less than a year, West Virginia's medical cannabis program has already added nearly 10,000 patients, and we look forward to supporting this thriving community. Trulieve is committed to providing the best quality services and products for the state's registered medical cannabis patients while strengthening community connections in this developing market."
Trulieve patients across West Virginia can choose from a large selection of THC and CBD products available in a variety of consumption methods, including flower, concentrates, tinctures, topicals, ingestibles, and more. Designed to meet every patient's needs, our portfolio of in-house brands includes Cultivar Collection, Momenta, Muse, TruFlower and more.
Last November , Trulieve opened West Virginia's first dispensary and has since expanded its store hours to welcome patients seven days a week. The Company has already opened four new dispensaries in the state this year, with plans to open three additional dispensary locations by the end of the year in Milton , Huntington and Belle .
For more information on store locations, please visit https://www.trulieve.com/dispensaries/west-virginia .
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .
Facebook: @Trulieve Instagram: @Trulieve_ Twitter: @Trulieve
Investor Contact Christine Hersey , Executive Director of Investor Relations +1 (424) 202-0210 Christine.Hersey@Trulieve.com
Media Contact Rob Kremer , Executive Director of Corporate Communications +1 (404) 218-3077 Robert.Kremer@Trulieve.com
MATTIO Communications Trulieve@Mattio.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-grand-opening-of-hurricane-wv-medical-dispensary-301580961.html
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2022/06/c0001.html
News Provided by Canada Newswire via QuoteMedia
Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf" or the "Company") a leading international provider of consumer products in cannabis, today announced that it will report its financial and operating results for the second quarter ended June 30, 2022 after market close on August 8, 2022 .
Management will host a conference call and audio webcast that evening at 5:00 p.m. ET consisting of prepared remarks followed by a question and answer session related to the Company's operational and financial highlights.
Curaleaf Second Quarter 2022 Financial Results Conference Call
+1-844-763-8274 (U.S.), +1-416-639-5883 (Canada) or +1-412-717-9224 (International)
https://ir.curaleaf.com/events
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 15, 2022 and can be accessed by dialing +1-877-344-7529 (U.S.), +1-855-669-9658 ( Canada ) or +1-412-317-0088 (International) and entering replay pin number: 4470743
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States , Curaleaf currently operates in 22 states with 134 dispensaries, 26 cultivation sites, and employs over 5,700 team members. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com .
Curaleaf IR Twitter Account: https://twitter.com/Curaleaf_IR
Investor Toolkit: https://ir.curaleaf.com/investor-toolkit
Investor Relations Website: https://ir.curaleaf.com/
Tracy Brady , SVP Corporate Communications
View original content: https://www.prnewswire.com/news-releases/curaleaf-to-report-second-quarter-2022-financial-and-operational-results-301580839.html
News Provided by PR Newswire via QuoteMedia
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.